Konishi T, Agawa S
Dept. of Surgery, Kanto Medical Center.
Gan To Kagaku Ryoho. 2000 May;27(5):655-70.
The diagnosis-related-group/prospective-payment system (DRG/PPS) was introduced into the health care system of the United States in 1983. This system triggered the development and implementation of clinical pathways aimed at reducing the length and cost of hospitalization. In Japan, trial use of a Japanese version of DRG/PPS was initiated in November 1998 in 10 hospitals under the control of the Ministry of Health and Welfare, and full-scale implementation of the system is expected in the near future. Clinical pathways, therefore, are a current focus of attention, mainly because of their success in enhancing management efficiency in the U.S. However, in actual clinical settings where clinical pathways are used, several Japanese health care providers have come to realize that they are also useful in improving staff coordination, patient satisfaction, and patient care, rather than simply reducing the length of hospital stay and cost of health care. The introduction of clinical pathways requires that treatment of the disease in question be defined and standardized. The implementation of pathways for the treatment of cancer, however, might prove difficult because of the high frequency of variation. In our experience, the main reason for the use of clinical pathways is not to reduce the number of variant cases but to provide high-quality care through the promotion of a team approach to treatment and enhanced patient care. Therefore, even if there were frequent variances following surgery for cancer, those occurring in accordance with the pathophysiological state of the patient would not interfere with management by clinical pathways. Clinical pathways are advantageous because they allow patients to know their treatment schedule; to prepare for hospitalization procedures; to have a better perspective on discharge; to reduce anxiety regarding hospital admission, even if it is the first time; to communicate better with doctors, nurses, and other medical care staff, leading to greater trust; and to improve their ability for self-management. These features are all important for the improvement of patient care. Furthermore, clinical pathways may lead to a situation in which the cost of hospitalization can be predicted prior to admission, enabling patients to compare differences between several hospitals. From our experience with gastric cancer, breast cancer, and esophageal cancer management, we consider clinical pathways to be of great benefit in helping to reform the current medical care system in regard to the management of cancer patients as well as patients with other diseases.
诊断相关分组/预付费系统(DRG/PPS)于1983年被引入美国医疗保健系统。该系统推动了旨在缩短住院时长和降低住院费用的临床路径的开发与实施。在日本,1998年11月在厚生省管控下的10家医院启动了日本版DRG/PPS的试用,预计该系统将在不久后全面实施。因此,临床路径成为当前关注的焦点,主要是因为它们在美国提高管理效率方面取得了成功。然而,在实际使用临床路径的临床环境中,一些日本医疗服务提供者逐渐意识到,临床路径不仅有助于缩短住院时间和降低医疗成本,还对改善医护人员协作、提高患者满意度以及提升患者护理质量有益。引入临床路径需要对相关疾病的治疗进行明确和标准化。然而,由于癌症治疗的变异频率较高,实施癌症治疗路径可能会面临困难。根据我们的经验,使用临床路径的主要原因并非减少变异病例的数量,而是通过促进团队治疗方法和加强患者护理来提供高质量的医疗服务。因此,即使癌症手术后出现频繁的变异情况,那些符合患者病理生理状态的变异也不会干扰临床路径的管理。临床路径具有诸多优势,它能让患者了解治疗计划;为住院程序做好准备;对出院有更清晰的认识;减少对住院的焦虑,即使是首次住院;更好地与医生、护士和其他医护人员沟通,从而增强信任;提高自我管理能力。这些特点对于改善患者护理都非常重要。此外,临床路径可能会使住院费用在入院前就能被预测,让患者能够比较几家医院之间的差异。根据我们在胃癌、乳腺癌和食管癌管理方面的经验,我们认为临床路径对于改革当前针对癌症患者以及其他疾病患者的医疗护理系统具有极大的益处。